MA41271A - Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 - Google Patents
Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7Info
- Publication number
- MA41271A MA41271A MA041271A MA41271A MA41271A MA 41271 A MA41271 A MA 41271A MA 041271 A MA041271 A MA 041271A MA 41271 A MA41271 A MA 41271A MA 41271 A MA41271 A MA 41271A
- Authority
- MA
- Morocco
- Prior art keywords
- antisens
- oligonucleotides
- methods
- targeting smad7
- smad7
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 101700026522 SMAD7 Proteins 0.000 title 1
- 102000049873 Smad7 Human genes 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462097012P | 2014-12-26 | 2014-12-26 | |
| US201562235269P | 2015-09-30 | 2015-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA41271A true MA41271A (fr) | 2017-10-31 |
Family
ID=56151259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA041271A MA41271A (fr) | 2014-12-26 | 2015-12-22 | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20190112608A1 (fr) |
| EP (1) | EP3237018A4 (fr) |
| JP (1) | JP2018502107A (fr) |
| KR (1) | KR20170105529A (fr) |
| CN (1) | CN107405413A (fr) |
| AU (1) | AU2015371325A1 (fr) |
| BR (1) | BR112017013765A2 (fr) |
| CA (1) | CA2971583A1 (fr) |
| CL (1) | CL2017001701A1 (fr) |
| CO (1) | CO2017007383A2 (fr) |
| EA (1) | EA201791471A1 (fr) |
| EC (1) | ECSP17040003A (fr) |
| IL (1) | IL253023A0 (fr) |
| MA (1) | MA41271A (fr) |
| MX (1) | MX2017008462A (fr) |
| SG (1) | SG11201705179TA (fr) |
| WO (1) | WO2016105516A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017004973A (es) | 2014-10-17 | 2017-12-07 | Nogra Pharma Ltd | Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7. |
| EP3420082A4 (fr) | 2016-02-23 | 2019-10-16 | Celgene Alpine Investment Company II, LLC | Méthodes de traitement de la fibrose intestinale par inhibition de smad7 |
| WO2018111323A1 (fr) * | 2016-12-14 | 2018-06-21 | Progenity Inc. | Méthodes et dispositifs ingérables pour la libération régio-spécifique d'inhibiteurs de smad7 au niveau du site d'une maladie du tractus gastro-intestinal |
| EP3554345A1 (fr) | 2016-12-14 | 2019-10-23 | Progenity, Inc. | Traitement d'une maladie du tractus gastro-intestinal avec un inhibiteur de smad7 |
| PE20210393A1 (es) | 2018-05-09 | 2021-03-02 | Ionis Pharmaceuticals Inc | Compuestos y metodos para la reduccion de la expresion de fxi |
| TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001241751B2 (en) * | 2000-02-23 | 2005-09-01 | Tel Aviv Sourasky Medical Center | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
| JP2005529152A (ja) * | 2002-05-17 | 2005-09-29 | プロテイン デザイン ラブス インコーポレイティド | 抗インターフェロンγ抗体を用いたクローン病又は乾癬の治療 |
| ITRM20030149A1 (it) * | 2003-04-02 | 2004-10-03 | Giuliani Spa | Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico |
| WO2008031014A1 (fr) * | 2006-09-08 | 2008-03-13 | Ore Pharmaceuticals Inc. | Procédé pour réduire ou soulager une inflammation dans le tube digestif |
| DK2099446T3 (da) * | 2006-11-17 | 2013-02-11 | Shire Dev Inc | Fremgangsmåde til behandling af inflammatorisk tarmsygdom |
| CA2734358A1 (fr) * | 2008-08-18 | 2010-02-25 | Glaxo Group Limited | Traitement d'une maladie auto-immune a l'aide d'antagonistes de l'il-18 |
| KR101921014B1 (ko) * | 2008-11-13 | 2018-11-21 | 노그라 파마 리미티드 | 안티센스 조성물 및 그의 제조 및 사용 방법 |
| TR201000680A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler |
| EP2748611B1 (fr) * | 2011-09-15 | 2016-11-23 | Nogra Pharma Limited | Méthodes pour surveiller la réactivité à un traitement anti-smad7 |
| US10473669B2 (en) * | 2014-05-09 | 2019-11-12 | Nogra Pharma Limited | Methods for treating inflammatory bowel disease |
| WO2015011694A2 (fr) * | 2014-10-17 | 2015-01-29 | Celgene Corporation | Isotopologues d'oligonucléotides antisens smad7 |
| EP3693736A3 (fr) * | 2014-10-17 | 2020-10-14 | Nogra Pharma Limited | Procédés de dosage et de surveillance de traitement d'oligonucléotides antisens smad7 utilisant des niveaux de biomarqueurs |
-
2015
- 2015-12-22 MA MA041271A patent/MA41271A/fr unknown
- 2015-12-23 US US15/539,497 patent/US20190112608A1/en not_active Abandoned
- 2015-12-23 SG SG11201705179TA patent/SG11201705179TA/en unknown
- 2015-12-23 EA EA201791471A patent/EA201791471A1/ru unknown
- 2015-12-23 AU AU2015371325A patent/AU2015371325A1/en not_active Abandoned
- 2015-12-23 EP EP15873796.5A patent/EP3237018A4/fr not_active Ceased
- 2015-12-23 BR BR112017013765A patent/BR112017013765A2/pt not_active IP Right Cessation
- 2015-12-23 CN CN201580076967.0A patent/CN107405413A/zh active Pending
- 2015-12-23 JP JP2017534594A patent/JP2018502107A/ja active Pending
- 2015-12-23 WO PCT/US2015/000269 patent/WO2016105516A1/fr not_active Ceased
- 2015-12-23 KR KR1020177020587A patent/KR20170105529A/ko not_active Withdrawn
- 2015-12-23 CA CA2971583A patent/CA2971583A1/fr not_active Abandoned
- 2015-12-23 MX MX2017008462A patent/MX2017008462A/es unknown
-
2017
- 2017-06-19 IL IL253023A patent/IL253023A0/en unknown
- 2017-06-23 CL CL2017001701A patent/CL2017001701A1/es unknown
- 2017-06-23 EC ECIEPI201740003A patent/ECSP17040003A/es unknown
- 2017-07-25 CO CONC2017/0007383A patent/CO2017007383A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015371325A1 (en) | 2017-07-13 |
| IL253023A0 (en) | 2017-08-31 |
| BR112017013765A2 (pt) | 2018-02-27 |
| WO2016105516A8 (fr) | 2017-07-06 |
| EP3237018A4 (fr) | 2018-07-11 |
| WO2016105516A1 (fr) | 2016-06-30 |
| US20190112608A1 (en) | 2019-04-18 |
| CA2971583A1 (fr) | 2016-06-30 |
| SG11201705179TA (en) | 2017-07-28 |
| MX2017008462A (es) | 2018-02-26 |
| JP2018502107A (ja) | 2018-01-25 |
| CL2017001701A1 (es) | 2018-04-06 |
| CO2017007383A2 (es) | 2018-01-05 |
| KR20170105529A (ko) | 2017-09-19 |
| ECSP17040003A (es) | 2017-10-31 |
| EA201791471A1 (ru) | 2017-12-29 |
| CN107405413A (zh) | 2017-11-28 |
| EP3237018A1 (fr) | 2017-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46481A (fr) | Compositions d'oligonucléotides et méthodes associées | |
| EP3324978A4 (fr) | Compositions d'oligonucléotides et méthodes associées | |
| PT3118311T (pt) | Ácido nucleico anti-sentido | |
| EP3224353C0 (fr) | Élimination ciblée de gènes bactériens | |
| MA45188A (fr) | Oligonucléotides, compositions et méthodes associées | |
| EP3328873A4 (fr) | Oligonucléotides ciblés | |
| IL250448A0 (en) | Modified double helix RNA materials | |
| EP3408391A4 (fr) | Oligonucléotides ramifiés | |
| EP3314027A4 (fr) | Oligonucléotides thérapeutiques | |
| PT3134506T (pt) | Métodos de purificação de rna mensageiro | |
| DK3200886T3 (da) | Spilsystem | |
| MA39481A (fr) | Thérapies ciblées | |
| DK3351633T3 (da) | Antisense-nukleinsyre | |
| DK3262066T4 (da) | Genterapi | |
| DK3107563T3 (da) | Glycomålrettede terapeutiske midler | |
| DK3231444T3 (da) | Ny behandling | |
| DK3149124T3 (da) | Anvendelse af lavmolekylære imid-holdige kvaternære ammoniumsalte | |
| MA46422A (fr) | Oligonucléotides modifiés et méthodes d'utilisation | |
| EP3409779A4 (fr) | Oligonucléotidique monocaténaire | |
| MA41642A (fr) | Variants de protoxine ii et méthodes d'utilisation | |
| MA41271A (fr) | Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7 | |
| DK3133923T3 (da) | Aav-based gene therapy for multiple sclerosis | |
| EP3362578A4 (fr) | Méthodes d'évaluation génomique du bétail | |
| IL249254A0 (en) | Gene expression system | |
| EP2953506A4 (fr) | Brosse cosmétique torsadée |